465. Deputy Gillian Toole asked the Minister for Health if the HPRA (Health Product Regulatory Authority) warning system will be inspected and upgraded in light of findings from the Food and Drug Administration in the United States where warnings about adverse events relating to Messenger RNA Covid vaccines were not on alerts. [75302/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions asked by Gillian Toole under the heading Medicinal Products.
5 questions match, newest first.
476. Deputy Gillian Toole asked the Minister for Health if information (details supplied) in relation to a series of matters regarding the policy, clinical and financial rationale for restricting access to long-acting injectable buprenorphine will be provided; and if she will make a statement on the matter. [33481/26]
554. Deputy Gillian Toole asked the Minister for Health the reason drug companies are indemnified if vaccines are presented to the public as being safe and effective. [29477/26]
558. Deputy Gillian Toole asked the Minister for Health the reason drug companies indemnified are if vaccines are presented to the public as being safe and effective. [29492/26]
588. Deputy Gillian Toole asked the Minister for Health when a review of the rate of value added tax on oral vitamin and mineral supplements, currently 13.5% rate, will be carried out; and the reason there is a disparity in VAT classification between oral pharmaceuticals, and oral supplements for health promotion; and if she will make a statement on the matter. [67255/25]